Forward Pharma FA ApS

The object of Forward Pharma FA ApS (the Company) is, to conduct business within development, manufacturing, distribution and sale of drugs and medicaments, as well as other related activities at the discretion of the board of directors. Furthermore, the Company may, within its line of business, participate in partnerships or co-operate with other businesses, including by licensing out rights within its line of business.

On March 9, 2023, the shareholder of Forward Pharma Operations ApS passed a resolution to begin the voluntary solvent liquidation of the Company. A liquidator of the Company has been appointed and on March 9, 2023, the resolution to liquidate the Company was registered with the Danish Business Authority.

Management estimates that the liquidation of the Company will be completed during the second half of 2023 or the first half of 2024. The decision to enter into voluntary solvent liquidation is not expected to impact the measurement of assets and liabilities at 31 December 2022.

The Company is a part of a Danish joint taxation group with NB FP Investment General Partner ApS, Forward Pharma A/S and Forward Pharma Operations ApS (the Company´s shareholder). Each company within the joint tax group is jointly and severally liable for Danish tax liabilities of the joint tax group. Any subsequent adjustments of corporation taxes may increase the Company’s liability.